ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

follitropin alfa

Also written as “Gonal-f”, “Follitropin alfa (Primapur)” and “Gonal-f®”.

Its studies are mostly in Infertility · Infertility, Female · Hypogonadism · Anovulation, led by 10 companies.

Drug pageFollitropin alfa: every studyMany companies study it; this page follows only the 23 they lead. All 49 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 4, 200523 company-led studies, 3 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germany131 open or runningphase 4since Nov 4, 2005Nov 4, 2005Sep 30, 2027phase 3 · NCT07340827
IVFarmaits history only20 open or runningphase 3since Mar 2, 2017Mar 2, 2017none ahead
Bharat Serums and Vaccinesits history only11 open or runningphase 3since Jan 23, 2022Jan 23, 2022none ahead
Changchun GeneScience Pharmaceuticalits history only10 open or runningphase 3since Jan 5, 2015Jan 5, 2015none ahead
Fertility Biotechits history only10 open or runningphase 1since May 19, 2015May 19, 2015none ahead
Finoxits history only10 open or runningphase 3since May 10, 2010May 10, 2010none ahead
Gema Biotechits history only10 open or runningphase 3since May 22, 2015May 22, 2015none ahead
IBSA Institut Biochimiqueits history only10 open or runningphase 3since Sep 15, 2006Sep 15, 2006none ahead
MinaPharm Pharmaceuticalsits history only10 open or runningphase 4since Nov 30, 2016Nov 30, 2016none ahead
Qilu Pharmaceuticalits history only11 open or runningphase 1since Mar 4, 2025Mar 4, 2025none ahead

Also a collaborator on its studies: Merck Serono Middle East FZ, Merck Serono GmbH, Germany, Merck Serono Co., Ltd., Japan and Merck Serono S.P.A., Italy.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck KGaA, Darmstadt, Germany only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 4, 2005First study: phase 4 study in InfertilityFirst studyNCT00249834 · 166 enrolled · France
  2. Jan 22, 2009Phase 4 study in InfertilityNCT00829244 · 200 enrolled · Switzerland
  3. Feb 18, 20102 phase 3 studiesNCT01071200, NCT01081639
  4. Mar 4, 2010Phase 4 study in InfertilityNCT01081626 · 310 enrolled · Kuwait, Lebanon, Saudi Arabia
  5. Aug 11, 20102 phase 3 studies in InfertilityNCT01185782, NCT01183143
  6. Dec 20, 2011Phase 3 study in InfertilityNCT01497197 · 174 enrolled · United Arab Emirates
  7. Jun 4, 2013Phase 4 study in InfertilityNCT01871532 · 24 enrolled · Ireland, United Kingdom
  8. May 19, 2021Phase 1 study in InfertilityNCT04899193 · 72 enrolled · China
  9. Jul 15, 2025Phase 1 study in HypogonadismNCT07097259 · 55 enrolled · United States
  10. Nov 17, 2025Phase 1 study in InfertilityNCT07269327 · 24 enrolled · United Kingdom
  11. Jan 6, 2026Phase 3 study in InfertilityNCT07340827 · 266 planned · Japan

Ahead

  1. Sep 30, 2027Primary completion: phase 3 study in InfertilityNCT07340827

TargetBeta

FSHR →read by rule
“Follicle stimulating hormone receptor agonist”ChEMBL 37, by rule

Other programs on FSHR

ProgramCompanyFurthest phaseStudies
Follicle Stimulating Hormoneruleglycotope-gmbhphase 46
follitropin deltaruleFerring Pharmaceuticalsphase 318

Studies

All 13 Merck KGaA, Darmstadt, Germany leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07340827Infertility · Japan3RecruitingSep 30, 2027266
NCT07269327Infertility · United Kingdom1CompletedMar 9, 202624
NCT07097259Hypogonadism · United States1CompletedDec 23, 202555
NCT04899193Infertility · China1CompletedMay 28, 202272
NCT01871532Infertility · Ireland, United Kingdom4TerminatedMar 201424
NCT01497197Infertility · United Arab Emirates3TerminatedJan 2014174
NCT01183143Infertility · Germany3CompletedMar 2, 2006215
NCT01185782Infertility · Japan3CompletedDec 2007300
NCT01081626Infertility · Kuwait, Lebanon, Saudi Arabia4CompletedMar 2011310
NCT01081639Infertility3CompletedSep 200434
NCT01071200Helping Behavior · Italy3TerminatedApr 2009133
NCT00829244Infertility · Switzerland4CompletedJan 2010200
NCT00249834Infertility · France4CompletedJan 16, 2006166

How it is read

Names in the registry

  • “Gonal-f”, 2 entries
  • “Follitropin alfa (Primapur)”, 2 entries
  • “Gonal-f®”, 2 entries
  • “GONAL-f®”, 2 entries
  • “GONAL f® prefilled pen”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.